Thông tin thuốc gốc
Chỉ định và Liều dùng
Adult: In patients with non-dystrophic myotonic disorders: Initially, 167 mg once daily. Doses may be increased based on the clinical response to 333 mg daily after at least 1 week, then may further increase to 500 mg daily after at least 1 further week of treatment. Maintenance: 167-500 mg daily. Max: 500 mg daily.

Ventricular arrhythmias
Adult: For rapid control of life-threatening cases: 400 mg loading dose, followed by 200 mg 8 hourly. When rapid control of life-threatening cases is not essential: Initially, 200 mg 8 hourly. Doses may be adjusted in increments or decrements of 50 or 100 mg at intervals of at least 2-3 days. Usual dose: 200-300 mg 8 hourly. Max: 400 mg 8 hourly. Treatment-responsive patients may be transferred to 12 hourly dosage schedule; if necessary, doses may be adjusted up to Max 450 mg 12 hourly.
Hepatic Impairment
Ventricular arrhythmias:
Dosage adjustment may be needed.
Mild to moderate: Dose may be increased only after at least 2 weeks of treatment.
Cách dùng
Should be taken with food.
Chống chỉ định
Cardiogenic shock, 2nd- or 3rd-degree atrioventricular (AV) block (without the presence of pacemaker).
Thận trọng
Patient with 1st-degree AV block, sinus node dysfunction, intraventricular conduction disturbances, CHF, hypotension, seizure disorders, and electrolyte imbalance (e.g. hypo- or hyperkalaemia, hypomagnesaemia); MI, abnormal Q-waves, symptomatic coronary artery disease, ventricular or atrial tachyarrhythmia, atrial flutter or fibrillation (for use in myotonia). Concomitant use with agents known to induce torsades de pointes. Treatment guidelines may vary among individual products (refer to product-specific recommendations). Hepatic impairment. Pregnancy and lactation.
Phản ứng phụ
Significant: Proarrhythmic effects (e.g. proarrhythmia, aggravation of arrhythmia), blood dyscrasias (e.g. leucopenia, agranulocytosis, thrombocytopenia), abnormal LFTs (e.g. markedly raised AST), drug reactions with eosinophilia and systemic symptoms (DRESS), seizures. Rarely, severe liver injury, hepatic necrosis.
Cardiac disorders: Tachycardia, palpitations, chest pain.
Ear and labyrinth disorders: Vertigo, tinnitus.
Eye disorders: Blurred vision, nystagmus.
Gastrointestinal disorders: Abdominal pain, nausea, vomiting, diarrhoea, constipation, heartburn.
General disorders and administration site conditions: Fatigue, malaise, asthenia, ataxia.
Musculoskeletal and connective tissue disorders: Tremors, arthralgia, pain in extremity.
Nervous system disorders: Headache, lightheadedness, dizziness, paraesthesia.
Psychiatric disorders: Insomnia, somnolence, confusion, depression, nervousness.
Respiratory, thoracic and mediastinal disorders: Dyspnoea.
Skin and subcutaneous tissue disorders: Acne, rash.
Vascular disorders: Flushing, hypotension.
Thông tin tư vấn bệnh nhân
This drug may cause blurred vision, confusion, and fatigue, if affected, do not drive or operate machinery.
Evaluate cardiac status (e.g. ECG, 24-48 hours Holter monitoring, echocardiography) before starting and periodically during treatment. Monitor and correct electrolyte disturbances prior to treatment initiation. Routinely check LFTs and blood pressure during treatment.
Quá liều
Symptoms: Paraesthesia, confusion, hallucination, drowsiness, seizure; nausea; sinus bradycardia, hypotension, CV collapse, and cardiac arrest (in extreme cases). Management: Supportive and symptomatic treatment. Give IV atropine to treat bradycardia with hypotension. Administer benzodiazepines for seizures.
Tương tác
Increased exposure and risk of toxic effects with inhibitors of CYP1A2 (e.g. ciprofloxacin, fluvoxamine) or CYP2D6 (e.g. propafenone, quinidine). Decreased plasma concentrations with inducers of CYP1A2 (e.g. omeprazole) or CYP2D6 (e.g. phenytoin, rifampicin, phenobarbital). May increase, decrease, or unchange the plasma concentrations with cimetidine. May increase the plasma concentrations of caffeine and theophylline.
Potentially Fatal: Increased risk of torsades de pointes with class Ia (e.g. procainamide, disopyramide), class Ic (e.g. flecainide, propafenone), and class III antiarrhythmics (e.g. amiodarone, sotalol).
Food Interaction
May decrease the rate but not the extent of absorption with food. Avoid dietary changes which may markedly alter the urinary pH as it may increase or decrease the excretion of mexiletine.
Tác dụng
Description: Mexiletine, a class 1B antiarrhythmic agent structurally similar to lidocaine, acts as a Na channel blocker by decreasing the rate of depolarisation of phase 0 of the action potential. It also increases the effective refractory period (ERP)/action potential duration (APD) ratio.
Onset: 30-120 minutes (loading dose regimen).
Absorption: Rapidly and almost completely absorbed from the gastrointestinal tract. Bioavailability: Approx 90%. Time to peak plasma concentration: 2-3 hours.
Distribution: Widely and rapidly distributed in the body. Crosses the placenta and enters breast milk. Volume of distribution: 5-9 L/kg. Plasma protein binding: Approx 50-70%.
Metabolism: Metabolised in the liver primarily by CYP2D6 and to a lesser extent by CYP1A2 isoenzyme into inactive metabolites (approx 90%) and major metabolites (e.g. p-hydroxymexiletine, hydroxy-methylmexiletine, and N-hydroxy-mexiletine).
Excretion: Via urine (10% as unchanged drug). Increased excretion with urinary acidification. Elimination half-life: Approx 10-12 hours.
Đặc tính

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 4178, Mexiletine. Accessed Oct. 26, 2020.

Bảo quản
Store between 15-30°C.
Phân loại MIMS
Phân loại ATC
C01BB02 - mexiletine ; Belongs to class Ib antiarrhythmics.
Anon. Mexiletine. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. Accessed 15/09/2020.

Anon. Mexiletine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 15/09/2020.

Buckingham R (ed). Mexiletine. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 15/09/2020.

Joint Formulary Committee. Mexiletine. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 15/09/2020.

Mexiletine Hydrochloride Capsule (Lannett Company, Inc.). DailyMed. Source: U.S. National Library of Medicine. Accessed 15/09/2020.

Namuscla 167 mg Hard Capsules (Lupin Europe GmbH). European Medicines Agency [online]. Accessed 15/10/2020.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Mexiletine từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2021 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi
  • Mexitil
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in